Sutro Biopharma (STRO) Price & Analysis

Compare

698 Followers

STRO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.52 - $4.60

Previous CloseN/A

Volume326.60K

Average Volume (3M)542.49K

Market Cap

$68.13M

Enterprise Value$74.93M

Total Cash (Recent Filing)$205.13M

Total Debt (Recent Filing)$19.59M

Price to Earnings (P/E)―

Beta3.87

Next Earnings

Nov 05, 2025

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding84,774,180

10 Day Avg. Volume498,277

30 Day Avg. Volume542,491

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.10

Enterprise Value/Revenue0.72

Enterprise Value/Gross Profit0.74

Enterprise Value/Ebitda-0.45

Forecast

1Y Price Target

$2.36

Price Target Upside184.34% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentThe company’s lead internal program, STRO-004, is expected to enter clinical development in the second half of 2025 via a Phase 1 basket trial.

InnovationSutro entered into a collaboration with the FDA’s Office of Pharmaceutical Quality to co-develop analytical standards for ADCs.

PartnershipsThe partnership with Astellas remains ongoing with one program entering IND-enabling toxicology, triggering a $7.5 million milestone payment.

Bears Say

Capital NeedsThe company may need additional capital in 2026 to ensure it reaches Phase 1 data with enough cash.

Collaboration ChallengesIpsen terminated the STRO-003 collaboration following a review of data and the ROR1 landscape.

Market PerformanceShares are down 58% year-to-date as the company's pivot to its earlier stage assets removes the prospect of any near-term data catalysts.

Sutro Biopharma News

Sutro Biopharma announces restructuring, workforce reduction of about 33%

Sutro Biopharma (STRO) announced an organizational restructuring to prioritize the advancement of its three ADC programs and research...

15d ago

STRO

Sutro Biopharma Announces Major Organizational Restructuring

Sutro Biopharma ( ($STRO) ) has shared an update. On September 29, 2025, Sutro Biopharma announced an organizational...

15d ago

STRO

Sutro Biopharma price target lowered to $4 from $7 at Jefferies

Jefferies lowered the firm’s price target on Sutro Biopharma (STRO) to $4 from $7 and keeps a Buy...

1M ago

STRO

Sutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial Cancers

Sutro Biopharma (($STRO)) announced an update on their ongoing clinical study. Sutro Biopharma’s recent clinical study update focuses...

2M ago

STRO

Sutro Biopharma price target lowered to $3 from $4 at Wells Fargo

Wells Fargo lowered the firm’s price target on Sutro Biopharma (STRO) to $3 from $4 and keeps an...

2M ago

STRO

Sutro Biopharma’s Strategic Shift and Pipeline Developments: A Hold Rating Amid Transitional Phase

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Hold rating on Sutro Biopharma. The associated price...

2M ago

STRO

Sutro Biopharma Advances ADC Pipeline and Reports Q2 2025 Results

Sutro Biopharma ( ($STRO) ) has released its Q2 earnings. Here is a breakdown of the information Sutro...

2M ago

STRO

Sutro Biopharma enters research collaboration with FDA for ADC standards

Sutro Biopharma (STRO) entered into a collaboration with the U.S. Food and Drug Administration to develop reference materials...

3M ago

STRO

Sutro Biopharma Faces NASDAQ Non-Compliance Notice

Sutro Biopharma ( ($STRO) ) has provided an announcement. On June 20, 2025, Sutro Biopharma received a notice...

4M ago

STRO

Sutro, Sarepta, Incyte, Signet, Wix: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($STRO) ), ( ($SRPT) ), ( ($INCY) ), ( ($SIG)...

4M ago

SIG

WIX

Piper upgrades Sutro Biopharma to Overweight on attractive valuation

Piper Sandler last night upgraded Sutro Biopharma (STRO) to Overweight from Neutral with an unchanged price target of...

4M ago

STRO

Sutro Biopharma upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler upgraded Sutro Biopharma (STRO) to Overweight from Neutral with an unchanged price target of $2. Published...

4M ago

STRO

Sutro Biopharma Adopts Key Proposals at Annual Meeting

Sutro Biopharma ( ($STRO) ) just unveiled an announcement. On June 6, 2025, Sutro Biopharma held its 2025...

4M ago

STRO

Sutro Biopharma appoints Greg Chow as CFO

Sutro Biopharma (STRO) announced the appointment of Greg Chow as CFO, effective June 2, 2025. Chow most recently...

4M ago

STRO

STRO FAQ

What was Sutro Biopharma Inc’s price range in the past 12 months?

Sutro Biopharma Inc lowest stock price was $0.52 and its highest was $4.60 in the past 12 months.

What is Sutro Biopharma Inc’s market cap?

Sutro Biopharma Inc’s market cap is $68.13M.

When is Sutro Biopharma Inc’s upcoming earnings report date?

Sutro Biopharma Inc’s upcoming earnings report date is Nov 05, 2025 which is in 22 days.

How were Sutro Biopharma Inc’s earnings last quarter?

Sutro Biopharma Inc released its earnings results on Aug 07, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.382 by $0.242.

Is Sutro Biopharma Inc overvalued?

According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sutro Biopharma Inc pay dividends?

Sutro Biopharma Inc does not currently pay dividends.

What is Sutro Biopharma Inc’s EPS estimate?

Sutro Biopharma Inc’s EPS estimate is -0.39.

How many shares outstanding does Sutro Biopharma Inc have?

Sutro Biopharma Inc has 84,774,180 shares outstanding.

What happened to Sutro Biopharma Inc’s price movement after its last earnings report?

Sutro Biopharma Inc reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.382. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Sutro Biopharma Inc?

Currently, no hedge funds are holding shares in STRO

Sutro Biopharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-347.64%

Trailing 12-Months

Asset Growth

-46.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma (STRO) Earnings & Revenues

Historic Earnings Reports

STRO Stock 12 Month Forecast

Average Price Target

$2.36

▲(184.34% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.9,1.1384615384615384,1.376923076923077,1.6153846153846154,1.853846153846154,2.0923076923076924,2.330769230769231,2.5692307692307694,2.807692307692308,3.046153846153846,3.2846153846153845,3.523076923076923,3.7615384615384615,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.9,1.0123076923076924,1.1246153846153846,1.2369230769230768,1.3492307692307692,1.4615384615384617,1.5738461538461537,1.6861538461538461,1.7984615384615386,1.9107692307692306,2.023076923076923,2.1353846153846154,2.2476923076923074,{"y":2.36,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.9,0.8923076923076924,0.8846153846153847,0.8769230769230769,0.8692307692307693,0.8615384615384616,0.8538461538461539,0.8461538461538461,0.8384615384615385,0.8307692307692308,0.8230769230769232,0.8153846153846154,0.8076923076923077,{"y":0.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.57,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.81,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >